M&A

AMAG Pharmaceuticals Announces Divestiture of Cord Blood Registry®

June 15, 2018

WALTHAM, Mass., June 15, 2018 (GLOBE NEWSWIRE) — AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced it has entered into a definitive agreement to divest Cord Blood Registry (CBR®) to GI Partners, a private equity investment firm, for $530 million in an all cash sale. The parties expect to close the transaction in the third quarter of […]

Sanofi and Recipharm announce transfer of Holmes Chapel Manufacturing site

June 14, 2018

Recipharm and Sanofi announced today that they have signed an agreement to transfer the Holmes Chapel site from global healthcare leader, Sanofi, to leading pharmaceutical contract development and manufacturing organisation, Recipharm. “Holmes Chapel brings Recipharm an ideal opportunity to accelerate its offering to customers with access to novel respiratory products. As an already successful CMO […]

Medidata Defines the Future of Life Sciences with Acquisition of SHYFT Analytics

June 12, 2018

NEW YORK–(BUSINESS WIRE)–Medidata (NASDAQ:MDSO) today announced that it has entered into a definitive agreement to acquire SHYFT Analytics, bringing the leading platform for clinical development together with the leading platform for commercial and real-world data analytics. “Medidata’s acquisition of SHYFT enables companies to better analyze clinical, real-world, and commercial data to achieve their goals.” Tweet […]

Takeda Announces Term Loan Credit Agreement and Amendment to Bridge Credit Agreement in Connection with Proposed Shire Acquisition

June 11, 2018

OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) announces that it has today entered into a term loan credit agreement for an aggregate principal amount of up to 7.5 billion USD with leading global financial institutions including J.P. Morgan Chase Bank N.A., Sumitomo Mitsui Banking Corporation, MUFG Bank, Ltd. and Mizuho Bank, Ltd. (the […]

BioTime Announces Submission of Draft Registration Statement for a Proposed Distribution of Its AgeX Shares

June 11, 2018

ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, announced that a draft registration statement on Form 10 was submitted to the U.S. Securities and Exchange Commission (the “SEC”). The draft registration statement relates to the proposed distribution of some or all of BioTime’s shares of AgeX Therapeutics, Inc. […]

VIVUS Executes on its Strategic Vision with the Closing of its Acquisition of PANCREAZE® and Previously Announced Financing Transaction

June 11, 2018

CAMPBELL, Calif., June 11, 2018 (GLOBE NEWSWIRE) — VIVUS, Inc. (Nasdaq:VVUS) (the “Company”), a biopharmaceutical company, today announced that it has met the closing conditions, including Hart-Scott-Rodino review, related to the Company’s previously announced acquisition of U.S. and Canadian rights to PANCREAZE® (pancrelipase) Delayed-Release Capsules for the treatment of exocrine pancreatic insufficiency (EPI) from Janssen […]

Biogen Enters Exclusive Option Agreement to Acquire TMS’ Phase 2 Asset for Acute Stroke

June 7, 2018

CAMBRIDGE, Mass., June 07, 2018 (GLOBE NEWSWIRE) — Biogen (Nasdaq:BIIB) announced today it has entered into an exclusive option agreement with TMS Co., Ltd. to acquire TMS-007 and backup compounds. The agreement includes an upfront payment of $4 million and an additional $18 million payment if Biogen exercises its option, with up to $335 million […]

Takeda and TiGenix Announce Results of First Acceptance Period for the Voluntary and Conditional Public Takeover Bid of TiGenix and Commencement of Second Acceptance Period

June 6, 2018

Osaka, Japan and Leuven, Belgium, June 6, 2018, 7h CET – Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) and TiGenix NV (Euronext Brussels and Nasdaq: TIG) (“TiGenix”) today announced the results of the first acceptance period of Takeda’s previously announced tender offer (the “Bid”) in cash for all outstanding ordinary shares (“Ordinary Shares”), warrants (“Warrants”) […]

Novartis completes sale of stake in consumer healthcare joint venture to GSK for USD13.0 billion

June 1, 2018

Basel, June 1, 2018 – Novartis AG (“Novartis”) today announced the completion of the divestment to GlaxoSmithKline PLC (“GSK”) of its 36.5 percent stake in a consumer healthcare joint venture (JV) for a total consideration of USD13.0 billion. The divestment was completed in accordance with the terms of the transaction announced on March 27, 2018 […]

WellCare to Buy Meridian State Health Plans for $2.5 Billion

May 31, 2018

WellCare Health Plans Inc. will buy two state insurance businesses and a pharmacy benefit manager from Meridian for $2.5 billion, bulking up the company’s Medicaid offerings in Michigan and Illinois.   The all-cash deal for Meridian Health Plan of Michigan Inc. and Meridian Health Plan of Illinois Inc. will give Tampa-based WellCare about 1.07 million […]

Myriad Genetics Signs Definitive Agreement to Acquire Counsyl, Inc.

May 29, 2018

SALT LAKE CITY, May 28, 2018 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it has signed a definitive agreement to acquire Counsyl, a pioneer in expanded carrier screening and non-invasive prenatal screening for $375 million through a combination of cash and Myriad common stock. […]

Avara Pharmaceutical Services Acquires Major Sterile Manufacturing Facility and Development Center in Canada

May 25, 2018

NORWALK, Conn., May 25, 2018 /PRNewswire/ — Avara Pharmaceutical Services, a world-class contract development and manufacturing organization (CDMO), today announced that it has agreed to acquire the largest sterile manufacturing facility for injectable medicines in Canada from a leading global pharmaceutical company, as part of a continuing expansion of its global footprint.   “This acquisition […]

Alexion Offer for Wilson Therapeutics Accepted

May 25, 2018

NEW HAVEN, Conn.–(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that its offer, through a wholly owned subsidiary, for the shares in Wilson Therapeutics has been accepted by shareholders representing 97.7 percent of the total number of shares and votes in Wilson Therapeutics. The acquisition has also been approved by relevant regulatory authorities. As more than […]

Takeda Makes $280M Divestiture Amid Shire Buy

May 24, 2018

Dive Brief: Following Takeda Pharmaceutical’s acquisition of rare disease biotech Shire, the Japanese pharma is divesting its 51.34% majority share of the Chinese biopharma Guangdong Techpool Bio-Pharma to its joint venture partner, Shanghai Pharmaceutical Holding. The purchase by Shanghai Pharmaceutical is supported by a fund managed by SFund International Investment Fund Management, a wholly-owned subsidiary […]

Allergan Exercises Option to Acquire Compound from Aptinyx Discovery Platform Under Ongoing Research Collaboration

May 23, 2018

EVANSTON, Ill., May 22, 2018 /PRNewswire/ — Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today announced Allergan plc (NYSE: AGN) has exercised its option to acquire drug candidate AGN-241751, an oral small-molecule N-methyl-D-aspartate (NMDA) receptor modulator. Aptinyx discovered AGN-241751 utilizing its proprietary chemistry platform and the compound was selected […]

Vitrisa Therapeutics Acquires Rights to MAKO Clinical Trial Data in wAMD

May 22, 2018

Results from MAKO Study to be used to help design and simulate clinical trials in wAMD LARKSPUR, Calif.–(BUSINESS WIRE)–Vitrisa Therapeutics, Inc., a Company focused on developing a suite of platform technologies optimized for ocular therapeutics and an associated pipeline of therapeutics in sight-threatening ocular diseases, today announced that it has entered into an option agreement […]

Allergan Exercises Option to Acquire Compound from Aptinyx Discovery Platform Under Ongoing Research Collaboration

May 22, 2018

EVANSTON, IL – May 22, 2018 – Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today announced Allergan plc (NYSE: AGN) has exercised its option to acquire drug candidate AGN-241751, an oral small-molecule N-methyl-D-aspartate (NMDA) receptor modulator. Aptinyx discovered AGN-241751 utilizing its proprietary chemistry platform and the compound was selected […]

Recipharm and Hadasit partner to deliver seamless chemical and clinical services

May 21, 2018

Recipharm, the contract development and manufacturing organisation (CDMO), has partnered with Hadasit Medical Research Services and Development to offer combined clinical, biological and chemical services. Located in Israel, Hadasit, a wholly owned subsidiary of Hadassah Medical Organisation (HMO), offers a variety of research, development and consulting services to customers, primarily in the Middle East. With […]

Novartis completes tender offer for all outstanding shares of AveXis, Inc.

May 15, 2018

Basel, May 15, 2018 – Novartis AG (NYSE: NVS) (“Novartis”) today announced the successful completion of the previously announced tender offer by its indirect wholly-owned subsidiary, Novartis AM Merger Corporation (“Purchaser”), for all the outstanding shares of common stock, par value $0.0001 per share, of AveXis, Inc. (NASDAQ: AVXS) (“AveXis”) at a price of USD […]

TapImmune and Marker Therapeutics Announce Entry into Merger Agreement, Creating a Transformational Immuno-Oncology Platform

May 15, 2018

JACKSONVILLE, Fla., May 15, 2018 /PRNewswire/ — TapImmune Inc. (NASDAQ: TPIV) (“TapImmune”) today announced that it has entered into a definitive merger agreement to acquire Marker Therapeutics, Inc. (“Marker”), a privately-held clinical-stage developer of a transformative, non-genetically engineered, multi-antigen T cell therapy platform. The proposed transaction will be a merger-of-equals under which the stockholders of […]

Lilly to Acquire AurKa Pharma

May 14, 2018

INDIANAPOLIS, May 14, 2018 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced an agreement to acquire AurKa Pharma, Inc., a company established by TVM Capital Life Science to develop oncology compound AK-01, an Aurora kinase A inhibitor that was originally discovered at Lilly. The compound is a potential first-in-class asset that AurKa Pharma […]

Lilly Announces Agreement To Acquire ARMO BioSciences

May 10, 2018

INDIANAPOLIS and REDWOOD CITY, Calif., May 10, 2018 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and ARMO BioSciences, Inc. (NASDAQ: ARMO) today announced a definitive agreement for Lilly to acquire ARMO for $50 per share, or approximately $1.6 billion, in an all-cash transaction. ARMO BioSciences is a late-stage immuno-oncology company that is developing a […]

Takeda-Shire Blockbuster Deal Comes With Big Risks: Max Nisen

May 10, 2018

After five proposals and more than month of back-and-forth, it looks like this thing is happening.   Takeda Pharmaceutical Co Ltd. agreed Tuesday to purchase rare-disease drugmaker Shire Plc for $62 billion. But this blockbuster deal comes with blockbuster risk. Takeda will be paying a steep premium and taking on big debt to acquire a […]

Lilly Announces Agreement To Acquire ARMO BioSciences

May 10, 2018

INDIANAPOLIS and REDWOOD CITY, Calif., May 10, 2018 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and ARMO BioSciences, Inc. (NASDAQ: ARMO) today announced a definitive agreement for Lilly to acquire ARMO for $50 per share, or approximately $1.6 billion, in an all-cash transaction. ARMO BioSciences is a late-stage immuno-oncology company that is developing a […]

Provention Bio Announces Agreements with MacroGenics for Two Clinical-Stage Assets for the Treatment of Autoimmune Disorders

May 9, 2018

OLDWICK, N.J., May 9, 2018 /PRNewswire/ — Provention Bio, Inc., a clinical-stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics aimed at intercepting and preventing immune-mediated diseases, announced today that it has entered into agreements with MacroGenics, Inc. involving two clinical-stage assets. Provention has acquired all rights to teplizumab to be further developed […]

ANI Pharmaceuticals Completes Acquisition of Generic Products and Assets from Amneal/Impax

May 8, 2018

BAUDETTE, Minn., May 7, 2018 /PRNewswire/ — ANI Pharmaceuticals, Inc. (“ANI”) (Nasdaq: ANIP) today announced that it has completed the acquisition of a portfolio of six generic products, related manufacturing and supply agreements, and equipment and technical know-how from Amneal Pharmaceuticals, LLC and Impax Laboratories, Inc. (NASDAQ: IPXL) for cash consideration of $2.3 million. The […]

Proposed Acquisition of Shire plc by Takeda

May 8, 2018

OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) and Shire plc (LON: SHP) (“Shire”) today announced that they have reached agreement on the terms of a recommended offer pursuant to which Takeda will acquire the entire issued and to be issued ordinary share capital of Shire. Under the terms of the acquisition, each Shire […]

Ardena acquires Syntagon and strengthens API offering

May 8, 2018

Contract development and manufacturing organisation (CDMO) Ardena has acquired Syntagon, a leading contract manufacturer of novel active pharmaceutical ingredients (APIs) and excipients. The acquisition, which is the CDMO’s first outside the Benelux region, expands its drug substance manufacturing capacity and means that bigger batch sizes up to 100 kg can now be handled by Ardena. […]

Janssen to Acquire BeneVir Biopharm to Advance Immunotherapy Regimens

May 2, 2018

HORSHAM, Pa., May 2, 2018 /PRNewswire/ — Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has entered into a definitive agreement under which it will acquire BeneVir Biopharm, Inc. (BeneVir), a privately-held, biopharmaceutical company specializing in the development of oncolytic immunotherapies. BeneVir utilizes a proprietary T-Stealth™ […]

FEEDBACK